(3) Nature and quantity of the products to be purchased :
A Letermovir (240mg 14tablets／case) 450cases
B Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30tablets／vial) 370vials
C Revlimid Capsules (5mg／capsule) 120-capsules
D ARIKAYCE (amikacin liposome inhalation suspension) (590mg／8.4mL) 210-vials
E Aflibercept (Genetical Recombination) (2mg 0.05ml／syringe) 470syringes
F Agalsidase Beta BS I.V. Infusion 35mg [JCR] (35mg／vial) 160vials
G Vutrisiran Sodium Kit (25mg 0.5ml／syringe) 10syringes
H Tocilizumab (Genetical Recombination) (200mg 10ml／vial) 1,500vials
I Tocilizumab (Genetical Recombination) (162mg 0.9ml／kit) 1,050cases
J Brentuximab Vedotin (Genetical Recombination) (50mg／vial) 80vials
K Paclitaxel (100mg／vial) 1,240vials
L Cetuximab (Genetical Recombination) (100mg 20ml／vial) 1,680vials
M Bevacizumab (Genetical Recombination) (400mg 16ml／vial) 380vials
N Infliximab BS for I.V.Infusion 100mg "NK" (100mg／vial) 2,350vials
O Durvalumab (Genetical Recombination) (500mg 10ml／vial) 920vials
P Canakinumab (Genetical Recombination) (150mg 1ml／vial) 30vials
Q Nivolumab (Genetical Recombination) (240mg 24ml／vial) 1,060vials
R Pembrolizumab (Genetical Recombination) (100mg 4ml／vial) 2,550vials
S Burosumab (Genetical Recombination) (30mg 1ml／vial) 70vials
T Trastuzumab Deruxtecan (Genetical Recombination) (100mg／vial) 540vials
U Freeze-driedpolyethylene glycol treated human normal immunoglobulin (5g 100ml／vial (with soluation)) (5g 100mL／vial) 870vials
V Polyethylene glycol treated human normal immunoglobulin (10g 100ml／vial) 680vials
W Tisagenlecleucel 3sets
X Pegfilgrastim (Genetical Recombination) (3.6mg 0.36mL／kit) 280kits
Y Ramucirumab (Genetical Recombination) (500mg 50ml／vial) 120vials
Z Palivizumab (Genetical Recombination) (100mg 1ml／vial) 470vials
AA Ustekinumab (Genetical Recombination) (45mg 0.5ml／syringe) 630syringes
AB Asfotase alfa (Genetical Recombination) (80mg 0.8ml／vial) 150vials
AC Pegfilgrastim (Genetical Recombination) (3.6mg 0.36ml／syringe) 550-syringes
AD Nusinersen Sodium (12mg 5ml／vial) 6vials
AE Risankizumab (Genetical Recombination) (150mg 1mL／syringes) 70syringes
AF Imiglucerase (Genetical Recombination) (400units／vial) 230vials
AG Eculizumab (Genetical Recombination) (300mg 30mL／vial) 100vials
AH Lanreotide Acetate (120mg／syringe) 150syringes
AI Daratumumab (Genetical Recombination) (400mg 20ml／vial) 170vials
AJ Daratumumab (Genetical Recombination) Vorhyaluronidase Alfa (Genetical Recombination) (15mL／vial) 80vials
AK Atezolizumab (Genetical Recombination) (1,200mg 20ml／vial) 400vials
AL Mepolizumab (Genetical Recombination) (100mg 1ml／kit) 380kits
AM Pertuzumab (Genetical Recombination) (420mg 14ml／vial) 170vials
AN Avelumab (Genetical Recombination) (200mg 10ml／vial) 250vials
AO Clazosentan Sodium (150mg 6mL／vial) 40vials
AP Benralizumab (Genetical Recombination) (30mg 1ml／syringe) 110syringes
AQ Panitumumab (Genetical Recombination) (100mg 5mL／vial) 360vials
AR Remdesivir (100mg／vial) 560vials
AS Mogamulizumab (Genetical Recombination) (20mg 5mL／vial) 260vials
AT Bevacizumab (Genetical Recombination) [Bevacizumab Biosimilar 2] (400mg 16mL／vial) 1,310vials
AU Ipilimumab (Genetical Recombination) (50mg 10ml／vial) 70vials
AV Ravulizumab (Genetical Recombination) (300mg 3ml／vial) 620vials
AW Denosumab (Genetical Recombination) (120mg 1.7ml／vial) 1,180vials
AX Elapegademase (Genetical Recombination) (2.4mg 1.5ml／vial) 50vials
AY Infliximab (Genetical Recombination) (100mg／vial) 1,630vials
AZ Romiplostim (Genetical Recombination) (250 μg／vial) 1,100vials
BA Galsulfase (Genetical Recombination) (5mg 5mL／vial) 220vials
BB Axicabtagene ciloleucel 1Set
(4) Delivery period : From 1 April, 2025 through 31 March, 2026
(5) Delivery place : Niigata University Medical and Dental Hospital
(6) Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 4 over the past one year and Article 3 of the Regulation concerning the Contract for Niigata University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B have the Grade A or Grade B qualification during fiscal 2024 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C prove to have obtained license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the President, National University Corporation Niigata University,
E meet the qualification requirements which President, National University Corporation Niigata University may specify in accordance with Article 5 of the Regulation,
F not be currently under a suspension of business order as instructed by President, National University Corporation Niigata University.
(7) Time limit of tender : 17 : 15　11 March, 2025
(8) Contact point for the notice : Yukiyo Aoyama, Procurement Section, Niigata University Medical and Dental Hospital, 754 Asahimachidori 1-bancho Chuo-ku Niigata-shi 951―8520 Japan, TEL 025―227―2430
(9) Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

入札公告

次のとおり一般競争入札に付します。
令和７年１月14日
国立大学法人東海国立大学機構
機構長　松尾　清一
◎調達機関番号　415　◎所在地番号　23
○第58号―名古屋大学
1　調達内容
(1)　品目分類番号　71、27
(2)　購入等件名及び数量　クラウド型特許管理システム　一式